The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.
Type 1 Diabetes for more than 3 years
BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis
Treated with GLP1-RAs within last 6 months
Known intolerance for semaglutide
Other forms of diabetes
Pregnant or nursing women
Nordsjaellands Hospital
Lead sponsor
Steno Diabetes Center Copenhagen
Collaborator
Steno Diabetes Center Odense
Collaborator
Zealand University Hospital
Collaborator
Aarhus University Hospital
Collaborator